Rep. Val T. Hoyle bought Gilead Sciences (GILD)
Rep. Val T. Hoyle (D-OR-4) · $1K–$15K · traded Oct 29, 2024
- Transaction
- Bought
- Amount
- $1K–$15K
- Owner
- Spouse
- Traded
- Oct 29, 2024
- Disclosed
- Sep 12, 2025
- Days to disclose
- 318 (after the 45-day deadline)
- Asset type
- Stock
- As filed
- Gilead Sciences, Inc. - Common Stock
- Industry
- Drug Manufacturers - General · Healthcare
Other trades in this filing
All of Hoyle's trades →- Sep 12, 2025$1K–$15K
Sold Walgreens Boots Alliance WBA
$1K–$15K · Traded Aug 27, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Aug 19, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Aug 19, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Aug 19, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Aug 19, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
Sold Johnson Controls International JCI
$1K–$15K · Traded Aug 19, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Aug 7, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Aug 7, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Aug 7, 2025 · disclosed Sep 12, 2025 · Spouse
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 28, 2025 · disclosed Sep 12, 2025 · Spouse · filed 46 days later
- Sep 12, 2025$1K–$15K
Sold The Goldman Sachs Group GS
$1K–$15K · Traded Jul 28, 2025 · disclosed Sep 12, 2025 · Spouse · filed 46 days later
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 28, 2025 · disclosed Sep 12, 2025 · Spouse · filed 46 days later
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 28, 2025 · disclosed Sep 12, 2025 · Spouse · filed 46 days later
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 28, 2025 · disclosed Sep 12, 2025 · Spouse · filed 46 days later
- Sep 12, 2025$1K–$15K
Sold The Sherwin-Williams Company SHW
$1K–$15K · Traded Jul 14, 2025 · disclosed Sep 12, 2025 · Spouse · filed 60 days later
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 14, 2025 · disclosed Sep 12, 2025 · Spouse · filed 60 days later
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 14, 2025 · disclosed Sep 12, 2025 · Spouse · filed 60 days later
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 14, 2025 · disclosed Sep 12, 2025 · Spouse · filed 60 days later
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 14, 2025 · disclosed Sep 12, 2025 · Spouse · filed 60 days later
- Sep 12, 2025$1K–$15K
$1K–$15K · Traded Jul 2, 2025 · disclosed Sep 12, 2025 · Spouse · filed 72 days later
Recent Congress trades in GILD
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026
- Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026 · Dependent
- Feb 26, 2026$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Jan 27, 2026 · disclosed Feb 26, 2026 · Joint
- Oct 10, 2025$1K–$15K
Rep. Val T. Hoyle (D-OR-4)
$1K–$15K · Traded Sep 23, 2025 · disclosed Oct 10, 2025 · Spouse
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 18, 2025$1K–$15K
Rep. Marjorie Taylor Greene (R-GA-14)
$1K–$15K · Traded Jun 6, 2025 · disclosed Jun 18, 2025
- Jun 11, 2025$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded May 14, 2025 · disclosed Jun 11, 2025 · Joint
Company context for GILD
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
GILD: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
GILD: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
GILD: third_quarter 2026 lobbying report
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Advocate on drug pricing proposals. Proposals to exp
Public: Oct 21, 2026, 1:36 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.